FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada) announced today it has entered an agreement with Appili Therapeutics (“Appili”) regarding the assignment of rights for the development and marketing of T-2307 outside of Japan.
Subject to terms of the agreement, FUJIFILM Toyama Chemical will transfer the development and marketing rights of the compound to Appili and receive milestones payments as well as royalties in the future.
T-2307, an antifungal candidate compound developed by FUJIFILM Toyama Chemical, exhibits it’s antifungal activity through a novel mode of action whereby it actively accumulates in fungal cells1 and is designed to selectively disrupt the function of fungal mitochondria2.
In the course of R&D with primary focus of targeting fungi, FUJIFILM Toyama Chemical has discovered and developed T-2307 for the treatment of various mycoses*3 including those due to drug resistant strains. The company continued to conduct clinical development of T-2307, including Phase I clinical trials in the United States.
Appili established in 2015 in Canada, is engaged in the R&D of drugs specializing in the area of infectious diseases. The company was listed in July 2019 on the Toronto Stock Exchange, and has been accelerating the development of new drugs. Through conclusion of this agreement, Appili plans to carry out a Phase II clinical trial of T-2307 targeting cryptococcal meningitis*4, a disease for which an effective treatment drug is being sought.
FUJIFILM Toyama Chemical has been promoting the R&D of treatment drugs with unique mode of action, focusing on “infectious diseases” as one of the key areas.
How useful was this post?
Click on a star to rate it!
Average rating / 5. Vote count:
No votes so far! Be the first to rate this post.
We are sorry that this post was not useful for you!
Let us improve this post!
Thanks for your feedback!